Icon (NASDAQ:ICLR) Stock Price Up 10.2% – Here’s What Happened

Shares of Icon Plc (NASDAQ:ICLR) were up 10.2% on Thursday . The stock traded as high as $128.06 and last traded at $130.54. Approximately 546,197 shares traded hands during trading, a decline of 65% from the average daily volume of 1,567,196 shares. The stock had previously closed at $118.45.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: BMO Capital Markets raised its target on Icon Plc to $160 from $130 and kept an outperform rating, suggesting meaningful upside potential. Benzinga
• Positive Sentiment: Barclays lifted its price target to $150 from $120, with an equal weight rating, signaling improved expectations for the stock. Tickerreport.com
• Positive Sentiment: Citigroup increased its target to $140 from $120, implying modest upside from current levels, though it kept a neutral stance. Tickerreport.com
• Neutral Sentiment: JPMorgan raised its target to $130 from $120 but kept a neutral rating, reflecting a more cautious view than some peers. Benzinga
• Neutral Sentiment: Icon reported fourth-quarter earnings that missed estimates, but revenue came in above expectations and the company highlighted strong bookings despite ongoing revenue challenges. Yahoo Finance
• Negative Sentiment: Icon disclosed a material weakness in internal controls, which raises concerns about financial reporting quality and potential regulatory risk. TipRanks
• Negative Sentiment: The company also cut FY 2026 EPS guidance to $10.00-$11.00, below Wall Street expectations, which likely pressured the stock after earnings. Financial News

Analysts Set New Price Targets

ICLR has been the topic of a number of research reports. Leerink Partners set a $145.00 price objective on Icon in a research note on Thursday. Citigroup lifted their target price on shares of Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday. Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. BMO Capital Markets raised their price objective on shares of Icon from $130.00 to $160.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Piper Sandler lowered shares of Icon to a “neutral” rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $153.00.

Icon Stock Down 0.5%

The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company has a market cap of $10.99 billion, a P/E ratio of 22.09, a price-to-earnings-growth ratio of 3.57 and a beta of 1.23. The company has a 50 day moving average of $113.06 and a 200-day moving average of $141.46.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, June 3rd. The medical research company reported $2.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.13 by ($0.61). Icon had a net margin of 7.40% and a return on equity of 10.58%. The company had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the prior year, the business earned $3.43 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, equities analysts predict that Icon Plc will post 11.53 earnings per share for the current year.

Institutional Trading of Icon

Hedge funds have recently made changes to their positions in the stock. Toth Financial Advisory Corp purchased a new stake in Icon during the fourth quarter valued at about $27,000. EFG International AG bought a new stake in Icon during the fourth quarter worth about $27,000. Ameriflex Group Inc. purchased a new position in shares of Icon in the 3rd quarter worth about $33,000. Abound Financial LLC purchased a new position in shares of Icon in the 4th quarter worth about $54,000. Finally, Johnson Financial Group Inc. bought a new position in shares of Icon during the 3rd quarter valued at about $71,000. 95.61% of the stock is owned by institutional investors.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.